Substance / Medication

Desvenlafaxine succinate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States.
Wang Manman, Yang Yingying, Hu Wei et al. · Clin Pharmacol Drug Dev · 2023
PMID: 37243511RCT
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff Leon, Gass Margery, Constantine Ginger et al. · Obstet Gynecol · 2008
PMID: 18165395Observational
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
DeMartinis Nicholas A, Yeung Paul P, Entsuah Richard et al. · J Clin Psychiatry · 2007
PMID: 17503976Observational
In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
da Silva Jéssica Domingos, de Sousa Valéria Pereira, Cabral Lucio Mendes et al. · AAPS PharmSciTech · 2020
PMID: 32666354Other
A Multi-layered Particulate System for Desvenlafaxine Succinate Oral Customized Release.
Elgindy Nazik, Elnoby Ayman, El-Gowelli Hanan M et al. · Curr Drug Deliv · 2017
PMID: 27211103Other
Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets.
Samy Wael, Elnoby Ayman, El-Gowelli Hanan M et al. · Saudi Pharm J · 2017
PMID: 28725139OtherFull text (PMC)
Intranasal bilosomes in thermosensitive hydrogel: advancing desvenlafaxine succinate delivery for depression management.
El-Nawawy Tayseer M, Adel Yomna A, Teaima Mahmoud et al. · Pharm Dev Technol · 2024
PMID: 38965754Preclinical
Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder.
Suh Jee Su, Minuzzi Luciano, Cudney Lauren E et al. · Neuroreport · 2019
PMID: 30741785Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Desvenlafaxine succinate (substance)
SNOMED CT
433292007
UMLS CUI
C1742884

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.